Anpilogova E M
Posters-Accepted Abstracts: J Clin Exp Dermatol Res
This clinical research was conducted at V.A. Rakhmanov Department of Skin and Venereal Diseases (the First Moscow State Medical University, Russia) and the Hematology Science Center (Moscow, Russia). We observed 8 patients with CTCL: 3 (37.5%) men and 5 (62.5%) women at the age of 50-56. The diagnoses were verified with histological, immunochistochemical and clonal hematological research methods. The duration of the disease ranged from 2 to 36 years. The patients had different stages of the CTCL: IA ? 3 patients, IB ? two patients, IIA ? one patient, IIB ? one patient. Before the treatment all the patients were fully examined; the contraindications for photochemotherapy were not revealed. The Hematology Science Center prescribed Reaferon (3 million units ? 3 times per week). At the same time the photochemotherapy based on skin exposure with UV (wavelength 320-400 nm) in 2 hours after ammifurin intake (photosensitizer) was applied in our clinic. The initial dose of the irradiation depended on the phototype of the patient?s skin and was 0.5-1.0 J/cm2. Photochemotherapy was carried out 4 times a week with gradually increasing dose of 0.5-1.0 J/cm2 in every 2 sessions to a single dose of 8-10 J/cm2. The course of therapy consisted of 20-30 procedures. After the combined therapy we reached the clinical remission in 75% of cases. The clinical behaviour was improved in 25% of cases (reduction and cessation of itching, blanching and flattering of lesions). At IA-IIA stage of CTCL the treatment was noted to be more effective.
Catherine Anpilogova is a senior student of the Center for Innovative Methods of Education ?The Medicine of the Future? at the I.M.Setchenov First Moscow State Medical University. She conducts research work in close conjunction with V.A.Rakhmanov Department of Skin and Venereal Diseases. She has published more than 8 papers in reputed journals.